Treatment Of Oropharyngeal Candidiasis By Oravig (Miconazole) Buccal Tablets

Treatment Of Oropharyngeal Candidiasis By Oravig (Miconazole) Buccal Tablets.
Strativa Pharmaceuticals today announced that the US Food and Drug Administration (FDA) has approved Oravig (miconazole) buccal tablets for the care of oropharyngeal candidiasis (OPC), more commonly known as thrush, in adults and children grow old 16 and older scriptovore.com. Oravig is the sooner and only local, word-of-mouth remedy formulation of miconazole - an antifungal medication - approved for this use in the US.

Oravig, which adheres to the gum, utilizes innovative buccal pad technology enabling once-daily dosing that delivers miconazole quickly at the city area of infection throughout the daylight with token systemic absorption provillus. Oravig is easy-to-use and provides patients with a flavorless, odorless and serviceable treatment option that does not interfere with regularly activities such as eating and drinking.

Oravig will be offered in a 50 mg dosage vigour and is expected to be available in retail pharmacies in the third thirteen weeks of 2010. "The FDA approval of Oravig underscores Strativa's commitment to improving patients' overall therapy experience by bringing to customer base new products that fulfill patient needs," said John A MacPhee, President, Strativa Pharmaceuticals. "Oravig offers patients agony from thrush a proven noticeable curing in a discreet and convenient once-daily formulation".

The FDA imprimatur was based on two pivotal Phase III clinical trials. The primary study demonstrated that Oravig unambiguously resolved signs and symptoms of OPC at rates similar to Mycelex Troche (clotrimazole) administered five times per prime in HIV-positive patients. This randomized, double-blind, double-dummy whack was conducted in 577 HIV-positive patients in 28 sites in the United States, Canada, and South Africa. A stand-in randomized, open-label, multicenter comparative test conducted in 282 patients who underwent radiotherapy for precede and neck cancer showed that Oravig is chest and real in this patient population who often has reduced salivary flow.

OPC is an voiced fungal infection most common in individuals with weakened unsusceptible systems - particularly those with HIV/AIDS and those undergoing infallible cancer treatments. OPC is a disruptive circumstance that results in lesions and inflammation in the mouth, and includes symptoms such as soreness, pain, parching and/or altered taste.

Oravig is approved in 26 countries and is currently being marketed in several EU territories including France, Germany and the UK under the job standing Loramyc. Under an trendy licensing agreement with BioAlliance Pharma, Strativa received the elegant US commercialization rights to Oravig (miconazole) buccal tablets. Under the terms of the agreement, the FDA endorsement triggered a $20 million milestone pay from Strativa to BioAlliance, for outright milestone payments to date in the amount of $35 million. In totting up to royalties on sales, BioAlliance may come into milestone payments on future sales.

Indication and Important Safety Information for Oravig. Oravig (miconazole) is indicated for the county healing of oropharyngeal candidiasis (OPC) in adults. Oravig (miconazole) is a buccal lozenge designed to adhere to the gum. Patients should be advised not to crush, chew, or accept the tablet.

During clinical trials, the most everyday adverse events (greater than or equal to 2%) reported with Oravig were diarrhea (6,0%), nausea (4,6%), inconvenience (5,0%), dysgeusia (2,9%), loftier abdominal pain (2,5%), and vomiting (2,5%). Oravig is contraindicated in patients with a known hypersensitivity to miconazole, draw off protein concentrate, or any other component of the product.

Allergic reactions, including anaphylactic reactions and hypersensitivity, have been reported with the superintendence of miconazole. Discontinue Oravig unhesitatingly at the anything else sign of hypersensitivity. There is no word regarding cross-hypersensitivity between miconazole and other azole agents neosize-xl. Monitor patients with a summary of hypersensitivity to azoles.